InVivo Therapeutics Holdings Corp., formerly Design Source, Inc., is a research and clinical-stage biomaterials and biotechnology company. The Company is engaged in developing and commercializing biopolymer-scaffolding devices for the treatment of spinal cord injuries (SCI). The Company's approach to treating acute SCIs is based on its investigational Neuro Spinal Scaffold implant, an investigational bioresorbable polymer scaffold that is designed for implantation at the site of injury within a spinal cord contusion and is intended to treat acute spinal cord injury. The Neuro-Spinal Scaffold consists of biocompatible and bioresorbable polymers, which include poly lactic-co-glycolic acid (PLGA) and Poly-L-Lysine (PLL). The Company is also evaluating other technologies and therapeutics that may be complementary to its development of the Neuro-Spinal Scaffold implant. The Company has a clinical development program for acute SCI and a preclinical development program for chronic SCI.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Advanced Medical Equipment & Technology
- Sub-Industry: N/A
- Symbol: OTCMKTS:NVIV
- CUSIP: N/A
- Web: www.invivotherapeutics.com/
- Market Cap: $45.06 million
- Outstanding Shares: 32,185,000
- 50 Day Moving Avg: $1.34
- 200 Day Moving Avg: $2.58
- 52 Week Range: $1.10 - $6.97
Sales & Book Value:
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -2.19
- P/E Growth: 0.00
- Annual Revenue: N/A
- Price / Sales: N/A
- Book Value: $0.59 per share
- Price / Book: 2.37
- EBIDTA: ($25,770,000.00)
- Return on Equity: -118.45%
- Return on Assets: -96.82%
- Average Volume: 407,656 shs.
- Short Ratio: 8.76
Frequently Asked Questions for Invivo Therapeutics Holdings Corp (OTCMKTS:NVIV)
What is Invivo Therapeutics Holdings Corp's stock symbol?
Invivo Therapeutics Holdings Corp trades on the OTCMKTS under the ticker symbol "NVIV."
How were Invivo Therapeutics Holdings Corp's earnings last quarter?
Invivo Therapeutics Holdings Corp (OTCMKTS:NVIV) posted its quarterly earnings results on Friday, November, 4th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.20) by $0.02. During the same quarter last year, the business posted ($0.22) earnings per share. View Invivo Therapeutics Holdings Corp's Earnings History.
When will Invivo Therapeutics Holdings Corp make its next earnings announcement?
Where is Invivo Therapeutics Holdings Corp's stock going? Where will Invivo Therapeutics Holdings Corp's stock price be in 2017?
1 analysts have issued 1 year target prices for Invivo Therapeutics Holdings Corp's stock. Their forecasts range from $6.00 to $6.00. On average, they anticipate Invivo Therapeutics Holdings Corp's stock price to reach $6.00 in the next twelve months. View Analyst Ratings for Invivo Therapeutics Holdings Corp.
Who are some of Invivo Therapeutics Holdings Corp's key competitors?
Some companies that are related to Invivo Therapeutics Holdings Corp include Edap Tms S.A. (EDAP), Fulgent Genetic (FLGT), Presbia PLC (LENS), Digirad Corporation (DRAD), Electromed (ELMD), Luna Innovations Incorporated (LUNA), Biolase (BIOL), EnteroMedics (ETRM), Advanced Oncotherapy PLC (AVO), Xtant Medical Holdings (XTNT), Dynatronics Corporation (DYNT), PhotoMedex (PHMD), Dextera Surgical (DXTR), Alliance HealthCare Services (AIQ), BIOLASE (BLTI), Cynosure (CYNO), Derma Sciences (DSCI) and Hansen Medical (HNSN).
Who are Invivo Therapeutics Holdings Corp's key executives?
Invivo Therapeutics Holdings Corp's management team includes the folowing people:
- Mark D. Perrin, Chairman of the Board, Chief Executive Officer
- Christopher McNulty, Principal Financial Officer and Principal Accounting Officer
- Melanie Morel-Ferris, Senior Director, Finance and Controller
- Tamara L. Joseph J.D., Senior Vice President, Chief Compliance Officer, General Counsel
- Thomas R. Ulich M.D., Chief Scientific Officer
- Pamela J. Stahl, Chief Commercial Officer
- Richard Toselli M.D., Chief Medical Officer
- Ann Merrifield, Lead Independent Director
- Jeffrey S. Hatfield, Director
- Christina T. Morrison, Director
Who owns Invivo Therapeutics Holdings Corp stock?
Invivo Therapeutics Holdings Corp's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (2.88%), Legal & General Group Plc (1.57%), Welch & Forbes LLC (1.25%), IMS Capital Management (1.22%), State Street Corp (1.20%) and Goldman Sachs Group Inc. (0.52%). View Institutional Ownership Trends for Invivo Therapeutics Holdings Corp.
Who sold Invivo Therapeutics Holdings Corp stock? Who is selling Invivo Therapeutics Holdings Corp stock?
Invivo Therapeutics Holdings Corp's stock was sold by a variety of institutional investors in the last quarter, including Northern Trust Corp, Vanguard Group Inc., Welch & Forbes LLC, State Street Corp, IMS Capital Management, Boston Financial Mangement LLC and Stifel Financial Corp. View Insider Buying and Selling for Invivo Therapeutics Holdings Corp.
Who bought Invivo Therapeutics Holdings Corp stock? Who is buying Invivo Therapeutics Holdings Corp stock?
How do I buy Invivo Therapeutics Holdings Corp stock?
Shares of Invivo Therapeutics Holdings Corp can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Invivo Therapeutics Holdings Corp's stock price today?
MarketBeat Community Rating for Invivo Therapeutics Holdings Corp (OTCMKTS NVIV)MarketBeat's community ratings are surveys of what our community members think about Invivo Therapeutics Holdings Corp and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Invivo Therapeutics Holdings Corp stock can currently be purchased for approximately $1.40.
Consensus Ratings for Invivo Therapeutics Holdings Corp (OTCMKTS:NVIV) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||1 Hold Rating|
|Consensus Rating:||Hold (Score: 2.00)|
|Consensus Price Target: ||$6.00|
Analysts' Ratings History for Invivo Therapeutics Holdings Corp (OTCMKTS:NVIV)
(Data available from 9/24/2015 forward)
|7/31/2017||Raymond James Financial, Inc.||Downgrade||Outperform -> Market Perform|
|7/21/2016||Ladenburg Thalmann Financial Services||Initiated Coverage||Buy||$23.25|
|5/12/2016||HC Wainwright||Reiterated Rating||Buy|
Earnings History for Invivo Therapeutics Holdings Corp (OTCMKTS:NVIV)Earnings History by Quarter for Invivo Therapeutics Holdings Corp (OTCMKTS NVIV)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
Earnings Estimates for Invivo Therapeutics Holdings Corp (OTCMKTS:NVIV)
Current Year EPS Consensus Estimate: $-0.78 EPS
Next Year EPS Consensus Estimate: $-0.64 EPS
Dividend History for Invivo Therapeutics Holdings Corp (OTCMKTS:NVIV)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Invivo Therapeutics Holdings Corp (OTCMKTS:NVIV)Insider Trades by Quarter for Invivo Therapeutics Holdings Corp (OTCMKTS:NVIV)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|5/9/2014||Francis Reynolds||Major Shareholder||Sell||50,000||$1.20||$60,000.00|| |
|5/5/2014||Francis Reynolds||Major Shareholder||Sell||37,500||$1.87||$70,125.00|| |
|4/30/2014||Francis Reynolds||Major Shareholder||Sell||37,500||$1.82||$68,250.00|| |
|4/25/2014||Francis Reynolds||Major Shareholder||Sell||50,000||$1.52||$76,000.00|| |
|4/21/2014||Francis Reynolds||Major Shareholder||Sell||50,000||$1.57||$78,500.00|| |
|4/14/2014||Francis Reynolds||Major Shareholder||Sell||37,500||$1.63||$61,125.00|| |
|4/9/2014||Francis Reynolds||Major Shareholder||Sell||37,500||$1.60||$60,000.00|| |
|4/4/2014||Francis Reynolds||Major Shareholder||Sell||25,000||$1.71||$42,750.00|| |
|4/2/2014||Francis Reynolds||Major Shareholder||Sell||37,500||$1.71||$64,125.00|| |
|3/26/2014||Francis Reynolds||Major Shareholder||Sell||47,900||$1.80||$86,220.00|| |
|3/21/2014||Francis Reynolds||Major Shareholder||Sell||39,600||$2.15||$85,140.00|| |
|3/17/2014||Francis Reynolds||Major Shareholder||Sell||37,500||$2.44||$91,500.00|| |
|3/12/2014||Francis Reynolds||Major Shareholder||Sell||37,500||$2.33||$87,375.00|| |
|3/7/2014||Francis Reynolds||Major Shareholder||Sell||25,000||$2.44||$61,000.00|| |
|3/5/2014||Francis Reynolds||Major Shareholder||Sell||37,500||$2.49||$93,375.00|| |
|2/28/2014||Francis Reynolds||Major Shareholder||Sell||25,000||$2.44||$61,000.00|| |
|2/26/2014||Francis Reynolds||Major Shareholder||Sell||37,500||$2.28||$85,500.00|| |
|2/21/2014||Francis Reynolds||Major Shareholder||Sell||25,000||$2.23||$55,750.00|| |
|2/19/2014||Francis Reynolds||Major Shareholder||Sell||25,000||$2.25||$56,250.00|| |
|2/14/2014||Francis Reynolds||Major Shareholder||Sell||25,000||$2.24||$56,000.00|| |
|2/12/2014||Francis Reynolds||Major Shareholder||Sell||37,500||$2.25||$84,375.00|| |
|2/7/2014||Francis Reynolds||Major Shareholder||Sell||25,000||$2.23||$55,750.00|| |
|2/5/2014||Francis Reynolds||Major Shareholder||Sell||37,500||$2.21||$82,875.00|| |
|1/31/2014||Francis Reynolds||Major Shareholder||Sell||25,000||$2.17||$54,250.00|| |
|1/29/2014||Francis Reynolds||Major Shareholder||Sell||37,500||$2.22||$83,250.00|| |
|1/24/2014||Francis Reynolds||Major Shareholder||Sell||25,000||$2.25||$56,250.00|| |
|1/21/2014||Francis Reynolds||Major Shareholder||Sell||37,500||$2.36||$88,500.00|| |
|1/15/2014||Francis Reynolds||Major Shareholder||Sell||37,500||$2.22||$83,250.00|| |
|1/10/2014||Francis Reynolds||Major Shareholder||Sell||48,000||$2.41||$115,680.00|| |
|1/6/2014||Francis Reynolds||Major Shareholder||Sell||36,000||$2.28||$82,080.00|| |
|12/31/2013||Francis Reynolds||Major Shareholder||Sell||36,000||$2.25||$81,000.00|| |
|12/26/2013||Francis Reynolds||Major Shareholder||Sell||36,000||$1.99||$71,640.00|| |
|12/20/2013||Francis Reynolds||Major Shareholder||Sell||24,000||$1.96||$47,040.00|| |
|12/18/2013||Francis Reynolds||Major Shareholder||Sell||36,000||$1.90||$68,400.00|| |
|12/13/2013||Francis Reynolds||Major Shareholder||Sell||24,000||$1.80||$43,200.00|| |
|12/11/2013||Francis Reynolds||Major Shareholder||Sell||36,000||$1.75||$63,000.00|| |
|12/6/2013||Francis Reynolds||Major Shareholder||Sell||24,000||$1.59||$38,160.00|| |
|12/4/2013||Francis Reynolds||Major Shareholder||Sell||36,000||$1.90||$68,400.00|| |
|11/22/2013||Francis Reynolds||Major Shareholder||Sell||24,000||$1.92||$46,080.00|| |
|11/20/2013||Francis Reynolds||Major Shareholder||Sell||36,000||$1.95||$70,200.00|| |
|11/13/2013||Francis Reynolds||Major Shareholder||Sell||36,000||$1.14||$41,040.00|| |
|11/8/2013||Francis Reynolds||Major Shareholder||Sell||24,000||$1.11||$26,640.00|| |
|11/6/2013||Francis Reynolds||Major Shareholder||Sell||36,000||$1.16||$41,760.00|| |
|11/1/2013||Francis Reynolds||Major Shareholder||Sell||24,000||$1.16||$27,840.00|| |
|10/30/2013||Francis Reynolds||Major Shareholder||Sell||36,000||$1.23||$44,280.00|| |
|10/25/2013||Francis Reynolds||Major Shareholder||Sell||24,000||$1.35||$32,400.00|| |
|10/22/2013||Francis Reynolds||Major Shareholder||Sell||24,000||$1.40||$33,600.00|| |
|10/18/2013||Francis Reynolds||Major Shareholder||Sell||24,000||$1.45||$34,800.00|| |
|10/16/2013||Francis Reynolds||Major Shareholder||Sell||36,000||$1.49||$53,640.00|| |
|10/11/2013||Francis Reynolds||Major Shareholder||Sell||24,000||$1.51||$36,240.00|| |
|10/9/2013||Francis Reynolds||Major Shareholder||Sell||36,000||$1.41||$50,760.00|| |
|10/4/2013||Francis Reynolds||Major Shareholder||Sell||24,000||$1.41||$33,840.00|| |
|9/20/2013||Francis Reynolds||Major Shareholder||Sell||24,000||$1.37||$32,880.00|| |
|9/18/2013||Francis Reynolds||Major Shareholder||Sell||36,000||$1.43||$51,480.00|| |
|9/13/2013||Francis Reynolds||Major Shareholder||Sell||24,000||$1.50||$36,000.00|| |
|9/11/2013||Francis Reynolds||Major Shareholder||Sell||24,000||$1.72||$41,280.00|| |
|9/6/2013||Francis Reynolds||Major Shareholder||Sell||24,000||$1.61||$38,640.00|| |
|9/4/2013||Francis Reynolds||Major Shareholder||Sell||24,000||$1.36||$32,640.00|| |
|9/3/2013||Sean F Moran||CFO||Buy||20,000||$1.02||$20,400.00|| |
|8/30/2013||Francis Reynolds||Major Shareholder||Sell||9,200||$1.55||$14,260.00|| |
|8/30/2013||Sean F Moran||CFO||Buy||40,000||$1.30||$52,000.00|| |
|8/28/2013||Francis Reynolds||Major Shareholder||Sell||12,600||$3.24||$40,824.00|| |
|8/23/2013||Francis Reynolds||Major Shareholder||Sell||21,300||$4.07||$86,691.00|| |
|8/21/2013||Francis Reynolds||CEO||Sell||36,000||$4.12||$148,320.00|| |
|8/16/2013||Francis Reynolds||CEO||Sell||24,000||$4.24||$101,760.00|| |
|8/14/2013||Francis Reynolds||CEO||Sell||36,000||$4.34||$156,240.00|| |
|8/9/2013||Francis Reynolds||CEO||Sell||24,000||$4.42||$106,080.00|| |
|8/7/2013||Francis Reynolds||CEO||Sell||36,000||$4.46||$160,560.00|| |
|8/2/2013||Francis Reynolds||CEO||Sell||24,000||$4.57||$109,680.00|| |
|7/30/2013||Francis Reynolds||CEO||Sell||24,000||$5.11||$122,640.00|| |
|7/26/2013||Francis Reynolds||CEO||Sell||24,000||$5.29||$126,960.00|| |
|7/24/2013||Francis Reynolds||CEO||Sell||36,000||$5.72||$205,920.00|| |
|7/19/2013||Francis Reynolds||CEO||Sell||24,000||$5.27||$126,480.00|| |
|7/17/2013||Francis Reynolds||CEO||Sell||36,000||$5.12||$184,320.00|| |
|7/12/2013||Francis Reynolds||CEO||Sell||24,000||$4.43||$106,320.00|| |
|7/10/2013||Francis Reynolds||CEO||Sell||36,000||$3.97||$142,920.00|| |
|7/5/2013||Francis Reynolds||CEO||Sell||12,000||$4.00||$48,000.00|| |
|7/3/2013||Francis Reynolds||CEO||Sell||36,000||$4.08||$146,880.00|| |
|6/28/2013||Francis Reynolds||CEO||Sell||24,000||$4.22||$101,280.00|| |
|6/26/2013||Francis Reynolds||CEO||Sell||36,000||$3.87||$139,320.00|| |
|6/21/2013||Francis Reynolds||CEO||Sell||24,000||$3.78||$90,720.00|| |
|6/19/2013||Francis Reynolds||CEO||Sell||36,000||$3.89||$140,040.00|| |
|6/14/2013||Francis Reynolds||CEO||Sell||24,000||$3.84||$92,160.00|| |
|6/12/2013||Francis Reynolds||CEO||Sell||12,750||$4.34||$55,335.00|| |
|6/7/2013||Francis Reynolds||CEO||Sell||8,500||$4.02||$34,170.00|| |
|6/5/2013||Francis Reynolds||CEO||Sell||12,750||$3.75||$47,812.50|| |
|6/5/2013||Robert Langer||Major Shareholder||Sell||7,500||$3.73||$27,975.00|| |
|5/31/2013||Francis Reynolds||CEO||Sell||8,500||$3.32||$28,220.00|| |
|5/31/2013||Robert Langer||Major Shareholder||Sell||7,500||$3.31||$24,825.00|| |
|5/29/2013||Francis Reynolds||CEO||Sell||8,500||$3.13||$26,605.00|| |
|5/28/2013||Robert Langer||Major Shareholder||Sell||7,500||$2.97||$22,275.00|| |
|5/24/2013||Francis Reynolds||CEO||Sell||8,500||$2.95||$25,075.00|| |
|5/22/2013||Robert Langer||Major Shareholder||Sell||7,500||$2.88||$21,600.00|| |
|5/21/2013||Francis Reynolds||CEO||Sell||12,750||$2.88||$36,720.00|| |
|5/17/2013||Francis Reynolds||CEO||Sell||8,500||$2.87||$24,395.00|| |
|5/17/2013||Robert Langer||Major Shareholder||Sell||7,500||$2.85||$21,375.00|| |
|5/15/2013||Francis Reynolds||CEO||Sell||12,750||$2.89||$36,847.50|| |
|5/14/2013||Robert Langer||Major Shareholder||Sell||7,500||$2.91||$21,825.00|| |
|5/10/2013||Francis Reynolds||CEO||Sell||8,500||$2.92||$24,820.00|| |
|5/9/2013||Robert Langer||Major Shareholder||Sell||7,500||$2.91||$21,825.00|| |
|4/12/2013||Francis Reynolds||CEO||Sell||8,500||$3.16||$26,860.00|| |
|2/5/2013||Francis Reynolds||CEO||Sell||12,750||$2.03||$25,882.50|| |
Headline Trends for Invivo Therapeutics Holdings Corp (OTCMKTS:NVIV)
Latest Headlines for Invivo Therapeutics Holdings Corp (OTCMKTS:NVIV)
Invivo Therapeutics Holdings Corp (NVIV) Chart for Sunday, September, 24, 2017